➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson
Colorcon

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OZANIMOD HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Ozanimod Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02531113 Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease Active, not recruiting Celgene Phase 2 2015-09-01 The purpose is to determine whether RPC1063 is effective in the treatment of Crohn's disease.
NCT02531126 Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis Recruiting Celgene Phase 3 2015-08-01 The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients diagnosed with moderate to severe ulcerative colitis.
NCT02576717 A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis Enrolling by invitation Celgene Phase 3 2015-10-01 The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis.
NCT03440372 Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease Recruiting Celgene Phase 3 2018-02-27 This is a Phase 3, randomized, double-blind, placebo-controlled study to explore the effect of oral ozanimod as an induction treatment for subjects with moderately to severely active Crohn's Disease.
NCT03440385 Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease Recruiting Celgene Phase 3 2018-03-07 This is a Phase 3, randomized, double-blind, placebo-controlled study to explore the effect of oral ozanimod as an induction treatment for subjects with moderately to severely active Crohn's Disease.
NCT03464097 A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease Not yet recruiting Celgene Phase 3 2018-07-31 This is a Phase 3, randomized, double-blind, placebo-controlled study to demonstrate the effect of oral ozanimod as maintenance therapy in subjects with moderately to severely active Crohn's Disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ozanimod Hydrochloride

Condition Name

Condition Name for Ozanimod Hydrochloride
Intervention Trials
Crohn Disease 4
Healthy Volunteers 3
Healthy Volunteer 3
Multiple Sclerosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ozanimod Hydrochloride
Intervention Trials
Crohn Disease 5
Colitis 2
Sclerosis 2
Multiple Sclerosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ozanimod Hydrochloride

Trials by Country

Trials by Country for Ozanimod Hydrochloride
Location Trials
United States 108
Canada 12
Australia 11
Brazil 8
Ukraine 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ozanimod Hydrochloride
Location Trials
Texas 9
California 7
Florida 7
Louisiana 5
Illinois 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ozanimod Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Ozanimod Hydrochloride
Clinical Trial Phase Trials
Phase 3 7
Phase 2/Phase 3 1
Phase 2 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ozanimod Hydrochloride
Clinical Trial Phase Trials
Not yet recruiting 7
Recruiting 6
Completed 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ozanimod Hydrochloride

Sponsor Name

Sponsor Name for Ozanimod Hydrochloride
Sponsor Trials
Celgene 16
Bristol-Myers Squibb 1
François Lellouche 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ozanimod Hydrochloride
Sponsor Trials
Industry 17
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Boehringer Ingelheim
McKinsey
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.